Program
ziltivekimab
Also written as “Ziltivekimab”, “Ziltivekimab B” and “Ziltivekimab C”.
Its studies are mostly in Renal Insufficiency, Chronic · Heart Failure · Myocardial Infarction · Coronary Artery Disease · Anemia, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordisk | 113 open or running | phase 3since Aug 19, 2021 | Mar 19, 2012 | Jan 29, 2027phase 3 · NCT06118281 |
| ECRI bv | 11 open or running | phase 3since Nov 28, 2025 | Nov 28, 2025 | Sep 1, 2028phase 3 · NCT07276282 |
- Named in Novo Nordisk’s own pipeline as
Ziltivekimab
, phase 3, as of Nov 5, 2026 (source).
Also a collaborator on its studies: corvidia-therapeutics and cardialysis-b-v.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 19, 2012First study: phase 1 study in Arthritis, RheumatoidNew to Novo NordiskNovo Nordisk · NCT01559103 · 39 enrolled · United States, Germany, United Kingdom
- Aug 9, 2016Phase 2 study in AnemiaNovo Nordisk · NCT02868229 · 61 enrolled · United States
- Apr 19, 2019Phase 2 study in Renal Insufficiency, ChronicNovo Nordisk · NCT03926117 · 264 enrolled · United States
- Nov 10, 2020Phase 2 study in Renal Insufficiency, ChronicNovo Nordisk · NCT04626505 · 36 enrolled · Japan
- Aug 19, 2021Phase 3 study in Renal Insufficiency, ChronicNovo Nordisk · NCT05021835 · 6,385 enrolled · United States, Argentina, Australia and more
- May 15, 2022Phase 1 study in Renal Insufficiency, ChronicNovo Nordisk · NCT05379829 · 24 enrolled · China
- Nov 23, 2022Phase 3 study in Heart FailureNovo Nordisk · NCT05636176 · 4,874 enrolled · United States, Argentina, Australia and more
- Feb 1, 2023Phase 1 study in Healthy ParticipantsNovo Nordisk · NCT05721989 · 267 enrolled · Hungary, Netherlands
- Oct 31, 2023Phase 3 study in Cardiovascular RiskNovo Nordisk · NCT06118281 · 10,000 enrolled · United States, Argentina, Australia and more
- Dec 28, 2023Phase 3 study in Heart FailureNovo Nordisk · NCT06200207 · 673 enrolled · United States, Argentina, Australia and more
- Nov 27, 2025Phase 3 study in Myocardial InfarctionNovo Nordisk · NCT07301034 · 332 planned · Austria, Denmark, Italy and more
- Nov 28, 2025ECRI bv's first study: phase 3 study in Coronary Artery DiseaseNew to ECRI bvECRI bv · NCT07276282 · 332 planned · Switzerland
Ahead
- Jan 29, 2027Primary completion: phase 3 study in Cardiovascular RiskNovo Nordisk · NCT06118281
- Sep 1, 2028Primary completion: phase 3 study in Coronary Artery DiseaseECRI bv · NCT07276282
- Nov 14, 2028Primary completion: phase 3 study in Myocardial InfarctionNovo Nordisk · NCT07301034
TargetBeta
“Interleukin-6 inhibitor; Interleukin-6 binding agent”ChEMBL 37, by rule
Other programs on IL6
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| olokizumabrule | R-Pharm | phase 3 | 19 |
| clazakizumab | CSL | phase 3 | 10 |
| pacibekitugrule | Novartis | phase 3 | 1 |
| isomyosaminerule | tnf-pharmaceuticals-inc | phase 2 | 1 |
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07276282Coronary Artery Disease · Switzerland | 3 | Recruiting | ECRI bv | Sep 1, 2028 | 332 |
| NCT07301034Myocardial Infarction · Austria, Denmark, Italy and more | 3 | Recruiting | Novo Nordisk | Nov 14, 2028 | 332 |
| NCT06200207Heart Failure · United States, Argentina, Australia and more | 3 | Active, not recruiting | Novo Nordisk | Oct 1, 2026 | 673 |
| NCT06118281Cardiovascular Risk · United States, Argentina, Australia and more | 3 | Active, not recruiting | Novo Nordisk | Jan 29, 2027 | 10,000 |
| NCT05721989Healthy Participants · Hungary, Netherlands | 1 | Completed | Novo Nordisk | Jan 8, 2024 | 267 |
| NCT05636176Heart Failure · United States, Argentina, Australia and more | 3 | Terminated | Novo Nordisk | Sep 3, 2026 | 4,874 |
| NCT05379829Renal Insufficiency, Chronic · China | 1 | Completed | Novo Nordisk | Jun 12, 2024 | 24 |
| NCT05021835Renal Insufficiency, Chronic · United States, Argentina, Australia and more | 3 | Completed | Novo Nordisk | Jun 9, 2026 | 6,385 |
| NCT04626505Renal Insufficiency, Chronic · Japan | 2 | Completed | Novo Nordisk | Aug 3, 2021 | 36 |
| NCT03926117Renal Insufficiency, Chronic · United States | 2 | Completed | Novo Nordisk | Jun 26, 2020 | 264 |
| NCT02868229Anemia · United States | 2 | Completed | Novo Nordisk | Dec 11, 2018 | 61 |
| NCT01559103Arthritis, Rheumatoid · United States, Germany, United Kingdom | 1 | Terminated | Novo Nordisk | Feb 28, 2014 | 39 |
How it is read
Names in the registry
- “Ziltivekimab”, 8 entries
- “Ziltivekimab B”, 2 entries
- “Ziltivekimab C”, 2 entries
- “COR-001”, 1 entry
- “MEDI5117”, 1 entry
Conditions, from the studies’ own filings
- Renal Insufficiency, Chronic, 4 studies
- Heart Failure, 2 studies
- Myocardial Infarction, 2 studies
- Coronary Artery Disease, 1 study
- Anemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.